Puma Biotechnology Initiates Phase 2 Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
10/4/2013 9:52:28 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced that it initiated a Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial).
Help employers find you! Check out all the jobs and post your resume.
comments powered by